Axovant Sciences Ltd. priced an underwritten public offering of 30 million common shares at $1 apiece to raise $30 million in gross proceeds.
The company granted the underwriters an option to buy up to an additional 4.5 million shares.
Axovant expects to close the offering Dec. 18, subject to customary closing conditions.
Jefferies and Guggenheim Securities are acting as joint book-running managers. JMP Securities is the lead manager, and H.C. Wainwright & Co. is the co-manager for the offering.
Axovant Sciences is a clinical-stage gene therapy company that develops treatments for debilitating neurological and neuromuscular diseases.